The Journal of Ophthalmic Inflammation and Infection, published by SPRINGER since 2011, stands as a pivotal resource for professionals in the fields of ophthalmology and infectious diseases. With an impactful Q2 ranking in both categories as of 2023, this open access journal is dedicated to disseminating high-quality research and reviews related to ocular inflammation and its infectious causes, fostering a deeper understanding of these critical health issues. The journal is well-regarded in the academic community, currently positioned at Rank #43 in Ophthalmology, reflecting its significance and influence within the discipline. The journal is accessible globally from its base in Germany, offering valuable insights to researchers, healthcare professionals, and students alike. With a commitment to excellence in publishing through 2024 and beyond, this journal continues to contribute meaningfully to innovative studies and clinical practices in ocular health.

CHEMOTHERAPY, published by KARGER, is a premier academic journal established in 1960, dedicated to disseminating cutting-edge research and advancements in the fields of drug discovery, infectious diseases, oncology, and pharmacology. With an impressive Scopus ranking placing it in the Q2 category for major disciplines such as Drug Discovery and Infectious Diseases, this journal provides an invaluable platform for researchers and professionals aiming to explore new therapeutic approaches and methodologies. Located in the heart of Switzerland, its publications are a key resource for anyone looking to stay informed about the latest developments and trends in the pharmacological sciences. Researchers can benefit from its diverse scope while contributing to a growing body of knowledge that emphasizes the importance of effective chemotherapeutic strategies in modern medicine. Despite not being an Open Access journal, CHEMOTHERAPY remains committed to maintaining a rigorous peer-review process, ensuring the highest quality of published work.

Emerging Infectious Diseases, published by the Centers for Disease Control and Prevention, is a leading open-access journal that has been dedicated to the field of epidemiology, infectious diseases, and medical microbiology since its inception in 1995. With an impressive impact factor placing it in the Q1 quartile rankings for multiple categories including Epidemiology, Infectious Diseases, and Medical Microbiology, this journal serves as a vital resource for researchers, practitioners, and students dedicated to combating the challenges posed by emerging infectious diseases. The journal's distinguished Scopus ranks further highlight its global influence, ranking #10 in Epidemiology, #26 in Infectious Diseases, and #13 in Medical Microbiology, all within the top percentiles. Accessible and targeted, Emerging Infectious Diseases publishes seminal research and reviews that contribute to the understanding and management of infectious diseases, ensuring that critical insights reach a broad audience. The journal encourages contributions that advance the scientific community’s knowledge and responses to public health challenges.

Current Treatment Options in Allergy is an esteemed academic journal published by SpringerNature, focusing on a critical area of health science: the evolving landscape of allergy treatments. With an E-ISSN of 2196-3053, this journal aims to provide a comprehensive platform for researchers and practitioners in the fields of Immunology and Allergy and Medicine. It has garnered recognition in the academic community, reflecting its significant contribution with a Q3 ranking in Immunology and Allergy and a Q3 ranking in Medicine as of 2023. The journal is based in Switzerland and encompasses research spanning from 2014 to 2024, ensuring that the latest findings and treatment options are available to professionals and students alike. With a growing focus on open access, it aims to make critical allergy treatment research widely accessible, thus fostering innovation and collaboration in this vital health sector. As the prevalence of allergies continues to rise globally, Current Treatment Options in Allergy plays a crucial role in disseminating important research and treatment strategies to improve patient outcomes.

Infectious Disease Reports is a premier open-access journal published by MDPI, dedicated to advancing the field of infectious diseases. Since its inception in 2009, this journal has established itself as a significant platform for disseminating cutting-edge research, reviews, and case studies, critical for global health. With a commendable Q2 ranking in the category of Infectious Diseases and a Scopus rank of #140 out of 344, it is recognized for its impactful contributions to medical research, holding a 59th percentile in its field. The journal aims to provide comprehensive insights into various dimensions of infectious diseases, ranging from epidemiology to novel treatment modalities. As an open-access publication, Infectious Disease Reports ensures that its articles are freely available to a wide audience, fostering collaborative efforts among researchers, healthcare professionals, and students worldwide. With its ongoing commitment to excellence, the journal plays an essential role in shaping the future of infectious disease research.

REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO is a prestigious open-access journal that has been publishing significant research in the field of tropical medicine since its inception in 1961. Produced by the Instituto de Medicina Tropical de São Paulo, the journal boasts a commendable Q3 ranking in both the categories of Infectious Diseases and Medicine (miscellaneous), as per the latest 2023 metrics. With an ISSN of 0036-4665 and E-ISSN of 1678-9946, it serves as a prominent platform for scholars and professionals to disseminate their findings and insights on pressing health issues prevalent in tropical regions, particularly those relevant to Brazil and beyond. This journal is essential for researchers and practitioners who seek to advance their understanding and apply innovative solutions in tropical medicine, thus addressing the distinct challenges posed by infectious diseases in diverse populations. The journal is accessible through various open access platforms, ensuring that critical research is available to a global audience, fostering knowledge sharing and collaboration.

Open Forum Infectious Diseases (ISSN: 2328-8957; E-ISSN: 2328-8957) is a leading open-access journal published by Oxford University Press, dedicated to advancing the field of infectious diseases. Since its inception in 2014, the journal has provided a platform for researchers to disseminate impactful findings in a rapidly evolving domain, achieving a remarkable Q1 ranking in both the Infectious Diseases and Oncology categories as of 2023. The journal encourages rigorous and innovative research, contributing significantly to global health discussions and informing best practices in clinical settings. As an open-access journal, it ensures that its content is accessible to a wide audience, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Positioned in the heart of the United States, Open Forum Infectious Diseases serves as a critical resource for the academic community, and its continued commitment to quality and relevance secures its status as an essential publication in the field.

Infectious Diseases, published by TAYLOR & FRANCIS LTD, is a leading academic journal dedicated to advancing research in the field of infectious diseases and microbiology. With an impressive impact factor and categorized in Q1 in multiple areas including Immunology and Microbiology, this journal serves as a critical platform for researchers, practitioners, and students to disseminate their findings and stay abreast of current advancements. The journal is recognized for its rigorous peer-review process and aims to foster innovation and collaboration across disciplines from 2015 to 2024. It boasts a robust Scopus ranking, positioning it favorably among the top-tier of journals in the relevant fields, making it an essential resource for anyone involved in infectious disease research. Access options are available, ensuring that the latest research is accessible to a global audience, thus emphasizing the journal's commitment to promoting knowledge and understanding in the ever-evolving landscape of infectious diseases.

JOURNAL OF INFECTION AND CHEMOTHERAPY, published by Elsevier, is a leading journal in the fields of Infectious Diseases, Microbiology, and Pharmacology. With a solid reputation reflected in its prestigious Q2 ranking in Infectious Diseases and Pharmacology, and Q3 in Microbiology (medical), this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements in the diagnosis, treatment, and prevention of infectious diseases. The journal provides a platform for high-quality, peer-reviewed scholarly articles, making it an essential reference point in the medical community. Despite being published without open access, it continues to attract significant scholarly attention, as denoted by its rankings in Scopus, which showcases its impact within the academic landscape. With a timeline converging from 1995 to 2024, JOURNAL OF INFECTION AND CHEMOTHERAPY is dedicated to advancing knowledge and contributing to better health outcomes globally.

JOURNAL DE MYCOLOGIE MEDICALE is a premier publication in the field of infectious diseases, particularly focusing on the study of mycology and its clinical implications. Published by MASSON EDITEUR, this esteemed journal is based in France and has been disseminating valuable research since its inception in 1994. With an ISSN of 1156-5233 and an E-ISSN of 1773-0449, it plays a critical role in advancing knowledge in mycological infections, positioning itself in the Q3 category for infectious diseases as per the 2023 quartiles. As indicated by its ranking in Scopus, ranking #142 out of 344 in the medicine-infectious diseases category, the journal maintains a prominent presence within the academic community, appealing to researchers, healthcare professionals, and students alike. Although access options are not open access, the journal endeavors to promote a deeper understanding of mycological studies that are crucial for combating ongoing and emerging infectious threats. As it continues to converge on new findings up to 2024, JOURNAL DE MYCOLOGIE MEDICALE remains an essential resource for those invested in the critical intersections of mycology and medicine.